The reporting-guideline ecosystem has grown to nearly 600 distinct guidelines tracked by the EQUATOR Network. For an author or editor staring at this in 2026, the question is not which guideline to applaud but which to actually use, when, and at what depth. This post walks through the four frameworks that anchor the field, the FAIR4RS guidelines for research software, and the registered-report turn that is reshaping pre-publication reproducibility commitments.
The four anchors
TOP Guidelines
The Transparency and Openness Promotion (TOP) Guidelines, developed at the Center for Open Science by Brian Nosek and colleagues, are the journal-policy framework rather than the per-paper checklist. TOP defines eight standards (citation, data transparency, analytic methods transparency, research materials transparency, design and analysis transparency, study preregistration, analysis-plan preregistration, replication) and three levels of stringency at which a journal can adopt each. A journal signing onto TOP commits to a profile of standard-by-standard adoption.
TOP’s contribution is structural: it gave editors a vocabulary to discuss reproducibility policies and a benchmark against which their journals could be assessed. By 2026 the TOP Factor (a score of journals’ policies against the TOP standards) is widely used to compare journal reproducibility commitments, alongside the more famous and less informative Journal Impact Factor. The CASRAI reproducibility standards page tracks the current TOP adoption ledger.
ARRIVE 2.0
The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments), revised in 2020 from the original 2010 version, are the canonical reporting standard for animal research. ARRIVE 2.0 introduced the Essential 10 (the must-report items) and the Recommended Set (the should-report items), which made the guideline more usable for both authors and reviewers.
ARRIVE adoption in 2026 is high in funder mandates (NIH, MRC, NC3Rs) but uneven in journal enforcement. The retrospective audits keep finding that even ARRIVE-required papers miss core items (randomisation method, blinding, sample-size justification). The lesson is that requiring a guideline at submission is not the same as enforcing it at peer review.
CONSORT 2010 and its extensions
The CONSORT 2010 statement is the reporting standard for randomised controlled trials and the most-cited reporting guideline in scholarly publishing. A CONSORT-compliant RCT report covers the title and abstract, methods (design, participants, interventions, outcomes, sample size, randomisation, blinding, statistical methods), results (participant flow, baseline data, primary and secondary outcomes, ancillary analyses, harms), and discussion (limitations, generalisability, interpretation). The CONSORT flow diagram (enrolled, allocated, followed-up, analysed) is itself a reportability artefact that has done more for trial transparency than most policy documents.
The 2025 revision of CONSORT (CONSORT 2025) is being finalised and is expected to integrate explicit reporting requirements for adaptive trial designs, machine-learning-derived endpoints, and patient-public involvement. The current standard is 2010 with several extensions (Cluster, Pragmatic, Non-pharmacological, Harms, Patient-reported outcomes, Outcomes, AI). Authors of any RCT should consult the relevant extension as well as the core standard.
PRISMA 2020
The PRISMA 2020 statement is the reporting standard for systematic reviews and meta-analyses. The 2020 revision modernised the 2009 original to reflect changes in search-and-screening practice (preprint searches, GitHub/OSF searches, ML-assisted screening), risk-of-bias assessment (ROB 2 for trials, ROBINS-I for non-randomised studies, AMSTAR-2 for review quality), and reporting formats (the PRISMA-S extension for search reporting, PRISMA-NMA for network meta-analyses).
PRISMA’s role in the systematic-review economy is dispositive: journals routinely refuse review submissions that do not include a PRISMA flow diagram and checklist. The remaining failure mode is checklist-completion-without-substance, where a paper ticks the boxes but the underlying review work is shallow.
Why these four anchors and not others
The four cover the bulk of submission volume in clinical and life-science journals: RCTs (CONSORT), systematic reviews (PRISMA), animal studies (ARRIVE), and the meta-question of journal policy (TOP). For observational studies, STROBE is the analogue of CONSORT; for diagnostic accuracy studies, STARD; for case reports, CARE; for qualitative research, SRQR or COREQ; for AI-clinical-prediction models, TRIPOD-AI and PROBAST-AI. The EQUATOR Network’s searchable database remains the canonical entry point.
Computational reproducibility
The reporting-guideline tradition was built around clinical and life-science studies. Computational reproducibility (your code, your data, your dependencies, run on your computer, gives the same answer) was historically not in scope and is now belatedly the focus of much of the methodological community’s attention.
The 2024-2025 convergence is around three pillars. First, data deposition in a FAIR-compliant repository with a DOI, with explicit licensing. Second, code deposition with a DOI (typically via Zenodo with a Git-tagged release), with explicit dependencies (environment files, container image hashes, or both). Third, computational environment via container (Docker, Singularity/Apptainer), or via a more lightweight pinned manifest (R’s renv, Python’s pip-tools, Julia’s Project.toml).
The FAIR4RS Principles, finalised by the RDA working group in 2022 and now widely cited, extend the FAIR data principles to research software. Software should be Findable (DOI, descriptive metadata), Accessible (open repository where possible), Interoperable (using standards), and Reusable (with a clear licence, documentation, and provenance). FAIR4RS is being integrated into funder data-management-plan requirements in 2026; the UK’s UKRI, the EU’s HORIZON Europe, and several US funders now ask for software-management plans as a distinct artefact from data-management plans.
Pre-registration and registered reports
Preregistration (committing to your hypotheses and analysis plan before seeing the data) has moved from a niche reproducibility-community practice to a mainstream expectation in psychology, parts of medicine, and increasingly in economics and political science. The Center for Open Science’s preregistration tools have crossed 200,000 registered studies; ClinicalTrials.gov and the WHO ICTRP carry the trial register.
The more interesting development is Registered Reports, a journal format in which a study protocol is peer-reviewed before data collection. If accepted at this Stage 1 review, the journal commits to publishing the Stage 2 manuscript regardless of whether the results are positive, negative, or null. Over 300 journals offer Registered Reports as of 2026, including several major medical journals. The empirical evidence is clear: Registered Reports show much lower positive-results rates than conventional submissions in the same fields, consistent with what we would expect if the conventional system suffers from publication bias.
How to use this in practice
For an author submitting a paper, the workflow is:
- Identify your study design and find the matching EQUATOR-listed reporting guideline (or guidelines, if multiple apply, e.g., a cluster RCT might use CONSORT plus the Cluster extension).
- Use the guideline’s checklist while drafting, not as a checkbox exercise at submission. The checklists are designed to prompt completeness.
- For computational components, deposit data and code with DOIs, declare dependencies, and consider a container if your environment is non-trivial.
- If your design supports it, consider preregistration or a Registered Report. The discipline of pre-specifying is itself the reproducibility intervention; the registration is the audit trail.
- In the methods, explicitly cite the guideline(s) you followed. Cite the deposited data and code with their DOIs in the references, not just in a parenthetical.
Where this all goes
The next wave of reporting-guideline work is around AI-clinical-prediction reporting (TRIPOD-AI, finalised in 2024; CLAIM for AI imaging studies), real-world-evidence studies (RECORD-PE, STaRT-RWE), and qualitative-meta-synthesis (ENTREQ). The structural question is whether the proliferation is helping or hurting. We think the answer is that the per-method guidelines are valuable but the cross-cutting transparency standards (TOP, FAIR, FAIR4RS, the registered-report meta-format) are doing the heavier lifting. Editors who pick a TOP profile and enforce it across submissions get more reproducibility uplift than editors who require a guideline checklist and then ignore the contents.
Related dictionary entries
References
EQUATOR Network, Reporting Guidelines for Health Research (continuously updated). Nosek et al., Promoting an open research culture (Science, 2015, introducing TOP). Page et al., The PRISMA 2020 statement (BMJ, 2021). Percie du Sert et al., The ARRIVE guidelines 2.0 (PLOS Biology, 2020). Chambers, The Seven Deadly Sins of Psychology (Princeton, 2017, on Registered Reports). RDA FAIR4RS Working Group, FAIR Principles for Research Software (2022).
